Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Multicenter Study Evaluating the Safety of ReAl-lifePertuzumab and Trastuzumab Fixed Dose Combination: the RAPID Study

NCT06835348 is registered in ClinicalTrials.gov with Fondazione Oncotech as lead sponsor.

NCT NCT06835348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06835348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Multicenter Study Evaluating the Safety of ReAl-lifePertuzumab and Trastuzumab Fixed Dose Combination: the RAPID Study
Lead sponsor
Fondazione Oncotech
Phase
Observational
Overall status
Completed
Start date
October 3, 2023
Completion date
November 29, 2024
Enrollment
80 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer